ACTRN12606000042549
Not yet recruiting
Not Applicable
A randomised phase III study evaluating the effectiveness and cost utility of the Minimum Dataset- Home Care (MDS-HC) assessment tool in comparison to the existing Needs and Service Coordination (NASC) assessment process to improve the quality of life for older people in the community requiring these assessment services.
Ministry of Health, New Zealand0 sites320 target enrollmentJanuary 27, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ministry of Health, New Zealand
- Enrollment
- 320
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Males and females aged 65 or greater years on the day of baseline examination; or aged 55 if of Mäori or Pacific Ethnicity and eligible for NASC/ OPAT services.2\.All participants must be eligible for assessment by the three designated MDS\-HC assessors.
Exclusion Criteria
- •1\.Those clients with a terminal illness and are currently receiving palliative care services2\.Participants directly transferred from hospital to permanent residential care after the initial assessment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Early inpatient-outpatient hospital-based pulmonary rehabilitation following hospitalisation for acute exacerbations of COPD: a randomised controlled studyChronic Obstructive Pulmonary Disease (COPD)Respiratory - Chronic obstructive pulmonary diseasePhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationACTRN12605000372684Green Lane Research and Educational Fund100
Active, not recruiting
Not Applicable
Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer. - Neostaton-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10025050Term: Lung cancer non-small cell stage IMedDRA version: 9.1Level: LLTClassification code 10025051Term: Lung cancer non-small cell stage IIMedDRA version: 9.1Level: LLTClassification code 10025052Term: Lung cancer non-small cell stage IIIMedDRA version: 9.1Level: LLTClassification code 10025053Term: Lung cancer non-small cell stage IIIAEUCTR2007-000903-14-GBImperial College, London184
Completed
Phase 3
PROphylaxis of ThromboEmbolism in Critical Care Trial (PROTECT)ThromboembolismCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12606000090516McMaster University3,650
Completed
Phase 3
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone in elderly patients with previously untreated systemic peripheral T-cell lymphomasT-cell lymphoma10025321NL-OMON41578niversity Medicine Goettingen25
Not yet recruiting
Phase 3
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomasT cell lymphoma10025321NL-OMON31642ordic Lymphoma Group40